← Human Trials & Peer-Reviewed Studies
Efficacy of intravenous magnesium sulfate infusion on postoperative pain and quality of recovery for septorhinoplasty: a randomized controlled study.
Plain-language guide to PMID 38108626 (2023): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 38108626
- Journal
- Acta oto-laryngologica
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Kilic K et al. (5 authors)
- DOI
- 10.1080/00016489.2023.2289584
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
To investigate the effect of perioperative intravenous magnesium sulfate infusion on postoperative pain and quality of recovery in patients underwent septorhinoplasty surgery.
Why It Was Studied
The pain that occurs after septorhinoplasty is an important factor affecting the comfort of the patient.
Who Took Part
One hundred twenty patients who underwent septorhinoplasty were randomly divided into two groups.
The VAS score was used for postoperative pain assessment, and the Quality of Recovery-40 (QoR-40) score was used for the assessment of recovery status.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
The placebo group received the same volume of saline infusion.
What Was Measured
The subject headings attached to it are Magnesium Sulfate, Magnesium and Postoperative Pain.
The authors tagged it with the keywords QoR-40, Septorhinoplasty and magnesium sulphate.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (Acta oto-laryngologica), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.